Anthracyclines in the Treatment of HER2 -Negative Breast Cancer
- 2 January 2008
- journal article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 100 (1), 2-4
- https://doi.org/10.1093/jnci/djm277
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized TrialsJNCI Journal of the National Cancer Institute, 2008
- Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast CancerJournal of Clinical Oncology, 2007
- Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast CancerJournal of Clinical Oncology, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Subgroup analyses in randomized trials: risks of subgroup-specific analyses;Journal of Clinical Epidemiology, 2004
- Molecular portraits of human breast tumoursNature, 2000
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 1999
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neuBreast Cancer Research and Treatment, 1992